The FDA has given some patients early access to the drug, daraxonrasib. A study being presented at an oncology conference in ...
A cancer-killing virus has stopped pancreatic tumours from growing and spreading in three people in an initial safety trial, ...
Money Talks News on MSN
New pancreatic cancer treatment tracks tumors through your entire body
Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in ...
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit explains why we are in a new era of progress against pancreatic ...
Researchers have demonstrated a promising new approach to stopping pancreatic cancer before it starts, using experimental drugs to eliminate microscopic precancerous lesions in the pancreas.
Morning Overview on MSN
A daraxonrasib trial just held pancreatic cancer in check for 8.5 months in most patients — twice as long as standard chemo for tumors that spread after first-line tr…
Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...
Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.
A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: ...
First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses. The WVU Cancer Institute is helping lead a global ...
Most significant change years in pancreatic cancer drug demand drives Mayo Clinic and others to expand access and patient education on daraxonrasib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results